Technical Analysis for TPST - Tempest Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.91 | -0.62% | -0.01 |
Earnings due: Nov 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -0.62% | |
| Stochastic Reached Oversold | Weakness | -0.62% | |
| Inside Day | Range Contraction | -0.62% | |
| Wide Bands | Range Expansion | -0.62% | |
| Oversold Stochastic | Weakness | -0.62% | |
| MACD Bearish Signal Line Cross | Bearish | -5.03% |
| Alert | Time |
|---|---|
| 1.5x Volume Pace | about 23 hours ago |
| Up 5% | about 23 hours ago |
| Up 3% | about 23 hours ago |
| Up 2% | about 23 hours ago |
| 60 Minute Opening Range Breakout | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/06/2024
Tempest Therapeutics, Inc. Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company's two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa. Its TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study agents as monotherapies and in combination with other approved agents. The company is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. The company is headquartered in South San Francisco, California. Tempest Therapeutics Inc. operates as a subsidiary of Inception Sciences, Inc.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Tumor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.0 |
| 52 Week Low | 0.88 |
| Average Volume | 3,454,268 |
| 200-Day Moving Average | 2.62 |
| 50-Day Moving Average | 1.25 |
| 20-Day Moving Average | 1.11 |
| 10-Day Moving Average | 1.03 |
| Average True Range | 0.13 |
| RSI (14) | 31.51 |
| ADX | 13.4 |
| +DI | 24.07 |
| -DI | 26.67 |
| Chandelier Exit (Long, 3 ATRs) | 1.21 |
| Chandelier Exit (Short, 3 ATRs) | 1.26 |
| Upper Bollinger Bands | 1.38 |
| Lower Bollinger Band | 0.84 |
| Percent B (%b) | 0.12 |
| BandWidth | 47.90 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.08 |
| MACD Histogram | -0.0129 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.02 | ||||
| Resistance 3 (R3) | 1.03 | 1.00 | 1.00 | ||
| Resistance 2 (R2) | 1.00 | 0.97 | 0.99 | 1.00 | |
| Resistance 1 (R1) | 0.95 | 0.95 | 0.94 | 0.95 | 0.99 |
| Pivot Point | 0.92 | 0.92 | 0.91 | 0.92 | 0.92 |
| Support 1 (S1) | 0.88 | 0.89 | 0.86 | 0.87 | 0.83 |
| Support 2 (S2) | 0.85 | 0.88 | 0.84 | 0.82 | |
| Support 3 (S3) | 0.80 | 0.85 | 0.82 | ||
| Support 4 (S4) | 0.80 |
